# Molecular Partners AG: Phase 1 study completed, 80 enrolled (Leukemia, Myeloid)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Molecular Partners AG |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome |
| NCT ID | NCT05673057 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Leukemia; Myeloid; Acute; Newly Diagnosed |
| Intervention types | drug |
| Target enrollment | 80 |
| Site countries | France, Lithuania, Netherlands, Switzerland |
| Posted | 2023-01-06 |
| Planned start | 2022-12-29 |
| Event | Completed |
| Event date | 2026-09-14 |
| Last update posted | 2026-09-25 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05673057). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.